Proton pump inhibitors increase the risk of carbapenem-resistant Enterobacteriaceae colonization by facilitating the transfer of antibiotic resistance genes among bacteria in the gut microbiome

Gut Microbes. 2024 Jan-Dec;16(1):2341635. doi: 10.1080/19490976.2024.2341635. Epub 2024 Apr 18.

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) pose a global health threat; however, there is still limited understanding of the risk factors and underlying mechanisms of CRE colonization in the gut microbiome. We conducted a matched case-control study involving 282 intensive care unit patients to analyze influencing covariates on CRE colonization. Subsequently, their effects on the gut microbiome were analyzed in a subset of 98 patients (47 CRE carriers and 51 non-CRE carriers) using whole metagenome sequences. The concomitant use of proton pump inhibitors (PPIs) and antibiotics was a significant risk factor for CRE colonization. The gut microbiome differed according to PPI administration, even within the CRE and non-CRE groups. Moreover, the transfer of mobile genetic elements (MGEs) harboring carbapenem resistance genes (CRGs) between bacteria was higher in the PPI-treated group than in the PPI-not-treated group among CRE carriers. The concomitant use of PPIs and antibiotics significantly alters the gut microbiome and increases the risk of CRE colonization by facilitating the transfer of CRGs among bacteria of the gut microbiome. Based on these findings, improved stewardship of PPIs as well as antibiotics can provide strategies to reduce the risk of CRE colonization, thereby potentially improving patient prognosis.

Keywords: Carbapenem-resistant enterobacteriaceae; antibiotic resistance gene; gut microbiome; metagenome-assembled genome; proton pump inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents
  • Bacteria
  • Carbapenem-Resistant Enterobacteriaceae*
  • Case-Control Studies
  • Drug Resistance, Microbial
  • Gastrointestinal Microbiome*
  • Humans
  • Proton Pump Inhibitors

Substances

  • Proton Pump Inhibitors
  • Anti-Bacterial Agents

Grants and funding

This research was supported by the Basic Science Research Program [2019R1I1A3A01060465, 2020R1A6A1A03043026, and 2021R1A6A1A03044501] through the National Research Foundation of Korea (NRF) funded by the Ministry of Education; and the Bio & Medical Technology Development Program of the NRF funded by the Ministry of Science and ICT [2021M3A9I4023974]; and the Korea National Institute of Infectious Diseases, Korea National Institute of Health [2023-ER2107-00].